Search

Your search keyword '"Costa, Daniel B."' showing total 881 results

Search Constraints

Start Over You searched for: Author "Costa, Daniel B." Remove constraint Author: "Costa, Daniel B."
881 results on '"Costa, Daniel B."'

Search Results

2. TIP60 is required for tumorigenesis in non‐small cell lung cancer

3. RSMA for Dual-Polarized Massive MIMO Networks: A SIC-Free Approach

4. Counteracting Eavesdropper Attacks Through Reconfigurable Intelligent Surfaces: A New Threat Model and Secrecy Rate Optimization

5. Rate-Splitting Multiple Access and its Interplay with Intelligent Reflecting Surfaces

8. IRS-Assisted Massive MIMO-NOMA Networks with Polarization Diversity

9. Understanding UAV-Based WPCN-Aided Capabilities for Offshore Monitoring Applications

10. IRS-Assisted Massive MIMO-NOMA Networks: Exploiting Wave Polarization

11. What Role Do Intelligent Reflecting Surfaces Play in Multi-Antenna Non-Orthogonal Multiple Access?

12. Safeguarding MIMO Communications with Reconfigurable Metasurfaces and Artificial Noise

13. Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial

14. Disparities in outcomes between Black and White patients in North America with thoracic malignancies and COVID-19 infection (TERAVOLT)

16. Analysis and Optimization of Tail-Biting Spatially Coupled Protograph LDPC Codes for BICM-ID Systems

18. On the Sum of Fisher-Snedecor F Variates and its Application to Maximal-Ratio Combining

21. On Multihop Weibull-Fading Communications: Performance Analysis Framework and Applications

23. An Effective Simultaneous Channel Estimation and Sensing Algorithm for mmWave MIMO-OFDM Systems

24. Tensor-Based Joint Symbol Detection, User Localization and Tracking for THz Systems With Dual-Wideband Effects

25. Cooperative Spectrum Sharing Relaying Protocols With Energy Harvesting Cognitive User

26. User-Pairing Scheme in NOMA Systems: A PSO-Based Approach

28. Association between immune-related adverse events and clinical outcomes to PD-1/PD-L1 blockade in small cell lung cancer

29. A Real-World Study of Patient Characteristics and Clinical Outcomes in EGFR Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into Routine Clinical Practice

31. On the Performance of Secure Full-Duplex Relaying under Composite Fading Channels

37. Data from Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial

38. Supplementary Data from Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial

42. Scientific Advances in Thoracic Oncology 2016

46. Data from TAS6417/CLN-081 Is a Pan-Mutation–Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations

47. Tables S1-3 and Figures S1-4 from TAS6417/CLN-081 Is a Pan-Mutation–Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations

Catalog

Books, media, physical & digital resources